Viewing Study NCT05907759


Ignite Creation Date: 2025-12-24 @ 2:35 PM
Ignite Modification Date: 2026-01-09 @ 11:27 AM
Study NCT ID: NCT05907759
Status: RECRUITING
Last Update Posted: 2025-07-01
First Post: 2023-06-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module